Baldrige Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Baldrige Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$1K	Buy	+64	New	+$717	﹤0.01%	359

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Baldrige Asset Management's IRWD Position: Q1 2023 in Review

Baldrige Asset Management opened a new position in Ironwood Pharmaceuticals (IRWD) in Q1 2023: 64 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #359 among its holdings.

254 funds tracked by Wall St. Rank hold IRWD as of Q1 2023.

Baldrige Asset Management held 64 shares of Ironwood Pharmaceuticals worth $1K as of Q1 2023.
Ironwood Pharmaceuticals was a new Baldrige Asset Management position in Q1 2023.
Ironwood Pharmaceuticals made up ﹤0.01% of Baldrige Asset Management's portfolio in Q1 2023, its #359 holding.
254 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2023.

Based on Baldrige Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.